CN116327791A - 一种治疗和预防新型冠状病毒的组合物及其制备方法 - Google Patents
一种治疗和预防新型冠状病毒的组合物及其制备方法 Download PDFInfo
- Publication number
- CN116327791A CN116327791A CN202310241187.3A CN202310241187A CN116327791A CN 116327791 A CN116327791 A CN 116327791A CN 202310241187 A CN202310241187 A CN 202310241187A CN 116327791 A CN116327791 A CN 116327791A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- mice
- treating
- lung
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title description 11
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims abstract description 34
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims abstract description 34
- LATYEZNGPQKAIK-UHFFFAOYSA-N 6'-O-benzoylpaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-UHFFFAOYSA-N 0.000 claims abstract description 17
- LATYEZNGPQKAIK-HRCYFWENSA-N Benzoylpaeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C=2C=CC=CC=2)O1)O)C)OC(=O)C1=CC=CC=C1 LATYEZNGPQKAIK-HRCYFWENSA-N 0.000 claims abstract description 17
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims abstract description 17
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims abstract description 17
- VIWQCBZFJFSCLC-UHFFFAOYSA-N alpha-benzoyloxypaeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(COC(=O)C=6C=CC=CC=6)O5)O)CC3(O)OC1C24COC(=O)C1=CC=C(O)C=C1 VIWQCBZFJFSCLC-UHFFFAOYSA-N 0.000 claims abstract description 17
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims abstract description 17
- DXDRHHKMWQZJHT-FPYGCLRLSA-N isoliquiritigenin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)C1=CC=C(O)C=C1O DXDRHHKMWQZJHT-FPYGCLRLSA-N 0.000 claims abstract description 17
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000008718 isoliquiritigenin Nutrition 0.000 claims abstract description 17
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims abstract description 17
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims abstract description 17
- 229960003908 pseudoephedrine Drugs 0.000 claims abstract description 17
- 229960001285 quercetin Drugs 0.000 claims abstract description 17
- 235000005875 quercetin Nutrition 0.000 claims abstract description 17
- IPQVTOJGNYVQEO-KGFNBKMBSA-N sennoside A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC2=C1C(=O)C1=C(O)C=C(C(O)=O)C=C1[C@@H]2[C@H]1C2=CC(C(O)=O)=CC(O)=C2C(=O)C2=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=CC=C21 IPQVTOJGNYVQEO-KGFNBKMBSA-N 0.000 claims abstract description 17
- IPQVTOJGNYVQEO-CXZNLNCXSA-N sennoside A Natural products O=C(O)c1cc(O)c2C(=O)c3c(O[C@H]4[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O4)cccc3[C@@H]([C@H]3c4c(c(O)cc(C(=O)O)c4)C(=O)c4c(O[C@H]5[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O5)cccc34)c2c1 IPQVTOJGNYVQEO-CXZNLNCXSA-N 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 claims abstract description 5
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 18
- QMNWISYXSJWHRY-YLNUDOOFSA-N astragaloside IV Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)[C@H]4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)C[C@H]3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-YLNUDOOFSA-N 0.000 claims description 12
- QMNWISYXSJWHRY-BCBPIKMJSA-N astragaloside IV Natural products CC(C)(O)[C@@H]1CC[C@@](C)(O1)[C@H]2[C@@H](O)C[C@@]3(C)[C@@H]4C[C@H](O[C@@H]5O[C@H](CO)[C@H](O)[C@@H](O)[C@H]5O)[C@H]6C(C)(C)[C@H](CC[C@@]67C[C@@]47CC[C@]23C)O[C@@H]8OC[C@@H](O)[C@H](O)[C@H]8O QMNWISYXSJWHRY-BCBPIKMJSA-N 0.000 claims description 12
- PFKIBRPYVNVMRU-UHFFFAOYSA-N cyclosieversioside F Natural products CC(C)(O)C1COC(C)(C1)C2C(O)CC3(C)C4CC(OC5OC(CO)C(O)C(O)C5O)C6C(C)(C)C(CCC67CC47CCC23C)OC8OCC(O)C(O)C8O PFKIBRPYVNVMRU-UHFFFAOYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 30
- 210000004072 lung Anatomy 0.000 description 74
- 241000699670 Mus sp. Species 0.000 description 50
- 210000001519 tissue Anatomy 0.000 description 40
- 239000003053 toxin Substances 0.000 description 24
- 231100000765 toxin Toxicity 0.000 description 24
- 230000002757 inflammatory effect Effects 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 20
- 244000309467 Human Coronavirus Species 0.000 description 18
- 206010035664 Pneumonia Diseases 0.000 description 17
- 241001678559 COVID-19 virus Species 0.000 description 16
- 238000001514 detection method Methods 0.000 description 16
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 14
- 241000699660 Mus musculus Species 0.000 description 14
- 102000048657 human ACE2 Human genes 0.000 description 14
- 238000011830 transgenic mouse model Methods 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 13
- 230000003612 virological effect Effects 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 208000011580 syndromic disease Diseases 0.000 description 9
- 238000005303 weighing Methods 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 241000711467 Human coronavirus 229E Species 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000002685 pulmonary effect Effects 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000003123 bronchiole Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 102400000921 Gastrin Human genes 0.000 description 4
- 108010052343 Gastrins Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 101800002372 Motilin Proteins 0.000 description 4
- 102400001357 Motilin Human genes 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 208000025721 COVID-19 Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000013456 study Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013691 Interleukin-17 Human genes 0.000 description 2
- 108050003558 Interleukin-17 Proteins 0.000 description 2
- 102000004125 Interleukin-1alpha Human genes 0.000 description 2
- 108010082786 Interleukin-1alpha Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 210000003456 pulmonary alveoli Anatomy 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 241001346334 Amomum tsao-ko Species 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022004 Influenza like illness Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001522129 Pinellia Species 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本申请涉及一种治疗和预防新型冠状病毒的组合物,该组合物的活性成分及其重量份为:厚朴酚55.7‑223份,伪麻黄碱10.7‑43份,番泻苷A 5.2‑20.6份,槲皮素4.3‑17.2份,苯甲酰芍药苷2.5‑10.3份,异甘草素0.43‑1.72份,黄芪甲苷1.3‑5.2份。该组合物具有治疗或预防新型冠状病毒的作用。
Description
技术领域:本申请属于中药领域,尤其涉及治疗新型冠状病毒领域。
背景技术:
新型冠状病毒是一种高度传染性的包膜阳性-RNA病毒,可致呼吸道疾病、发热和肺炎的发生。中药复方(TCMFs)的研发得到了大力支持,广泛用于COVID-19的预防治疗。化湿败毒方为抗COVID-19著名中药复方,由14味中药组成,包括君药:麻黄,广藿香,石膏;臣药:苦杏仁,半夏,厚朴,苍术,草果,茯苓;佐药:黄芪,南葶苈子,大黄;使药:甘草。化湿败毒方,临床研究表现方药可促进SARS-CoV-2RNA清除,肺部混浊吸收,减轻炎症,改善流感样症状,具有潜在的抗病毒和抗炎活性。前期研究已初步鉴定了化湿败毒方中有217种化学成分。为了进一步研究化湿败毒方中的活性成分,通过前期的化学、药理学相关研究,确定其活性成分,并进行体内外药效学实验确定了活性成分的组合物,用于治疗和预防新型冠状病毒。
发明内容:为了得到化湿败毒方中的活性成分组合物,本申请通过大量的化学、药理学相关研究,最终筛选得到一种治疗和预防新型冠状病毒的组合物。
本申请涉及的治疗和预防新型冠状病毒组合物的活性成分及其重量份为:厚朴酚55.7-223份,伪麻黄碱10.7-43份,番泻苷A 5.2-20.6份,槲皮素4.3-17.2份,苯甲酰芍药苷2.5-10.3份,异甘草素0.43-1.72份,黄芪甲苷1.3-5.2份;或为厚朴酚100-180份,伪麻黄碱20-35份,番泻苷A 8.4-15.8份,槲皮素7.5-15.2份,苯甲酰芍药苷4.5-9.6份,异甘草素0.56-1.35份,黄芪甲苷2.1-4.5份;或为厚朴酚100份,伪麻黄碱20份,番泻苷A 8.4份,槲皮素7.5份,苯甲酰芍药苷4.5份,异甘草素0.56份,黄芪甲苷2.1份;或为厚朴酚180份,伪麻黄碱35份,番泻苷A 15.8份,槲皮素15.2份,苯甲酰芍药苷9.6份,异甘草素1.35份,黄芪甲苷4.5份;或为厚朴酚111.5份,伪麻黄碱21.5份,番泻苷A 10.3份,槲皮素8.6份,苯甲酰芍药苷5.15份,异甘草素0.86份,黄芪甲苷2.6份。
本申请所述组合物制成药物时的剂型为颗粒剂、片剂、胶囊、口服液或注射剂等。
本申请所述治疗和预防新型冠状病毒的药物,将上述组合物与药学上可接受的载体或赋形剂制成药物制剂;
本申请所述的组合物或药物在制备治疗或预防新型冠状病毒的药物中的应用。
本申请所述组合物具有预防或治疗新型冠状病毒的作用。
本申请所述厚朴酚,伪麻黄碱,番泻苷A,槲皮素,苯甲酰芍药苷,异甘草素,黄芪甲苷可由中药材采用本领域提取方法提取制备得到,或市售商品直接购买得到。
下面,通过具体实施例来阐述本申请的技术方案。
附图说明:
图1组合物对SARS-CoV-2感染人类ACE2(hACE2)转基因小鼠体重的影响
图2组合物对SARS-CoV-2感染人类ACE2(hACE2)转基因小鼠病毒载量的影响
图3组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中趋化因子MCP-1的影响
图4组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中趋化因子MIP-1α的影响
图5组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中趋化因子IP-10的影响
图6组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子TNF-α的影响
图7组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子IL-6的影响
图8组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子IFN-γ的影响
图9组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子IL-17的影响
图10组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子IL-10的影响
图11组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子IL-12的影响
图12组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织中炎症因子IL-1α的影响
图13 SARS-CoV-2感染人类ACE2转基因小鼠模型对照组肺组织病理HE染色结果,表现为中度间质性肺炎(200×)
图14组合物对SARS-CoV-2感染人类ACE2转基因小鼠肺组织病理HE染色结果,表现为轻度间质性肺炎(200×)
具体实施方式:
实施例1:
一种组合物,其原料药为:厚朴酚111.5mg,伪麻黄碱21.5mg,番泻苷A 10.3mg,槲皮素8.6mg,苯甲酰芍药苷5.15mg,异甘草素0.86mg,黄芪甲苷2.6mg,组合物制备成口服液的制备方法包括:依次称取上述各活性成分,充分混匀,添加药学可接受的载体制备成口服液。
实施例2:
一种组合物,其原料药为:厚朴酚180mg,伪麻黄碱35mg,番泻苷A 15.8mg,槲皮素15.2mg,苯甲酰芍药苷9.6mg,异甘草素1.35mg,黄芪甲苷4.5mg,组合物制备成颗粒剂的制备方法包括:依次称取上述各活性成分,充分混匀,添加药学可接受的载体制备成颗粒剂。
实施例3:
一种组合物,其原料药为:厚朴酚100mg,伪麻黄碱20mg,番泻苷A 8.4mg,槲皮素7.5mg,苯甲酰芍药苷4.5mg,异甘草素0.56mg,黄芪甲苷2.1mg,组合物制备成胶囊剂的制备方法包括:依次称取上述各活性成分,充分混匀,添加药学可接受的载体制备成胶囊剂。
实施例4:
一种组合物,其原料药为:厚朴酚55.7mg,伪麻黄碱10.7mg,番泻苷A 5.2mg,槲皮素4.3mg,苯甲酰芍药苷2.5mg,异甘草素0.43mg,黄芪甲苷1.3mg,组合物制备成片剂的制备方法包括:依次称取上述各活性成分,充分混匀,添加药学可接受的载体制备成片剂。
实施例5:
一种组合物,其原料药为:厚朴酚223mg,伪麻黄碱43mg,番泻苷A 20.6mg,槲皮素17.2mg,苯甲酰芍药苷10.3mg,异甘草素1.72mg,黄芪甲苷5.2mg,组合物制备成注射剂的制备方法包括:依次称取上述各活性成分,充分混匀,添加药学可接受的载体制备成注射剂。
药效学实验1:组合物对新冠病毒性肺炎的效果
2.1材料与方法
伦理声明小鼠感染性操作均在生物安全三级实验室内进行,所有实验程序均经中国医学科学院医学实验动物研究所&北京协和医院比较医学中心动物保护与使用委员会批准(BLL21008)。
病毒:SARS-CoV-2/human/CHN/Delta-2/2021(Genbank:OM061695)由中国医学科学院医学实验动物研究所提供。
2.2动物实验
6~8周龄SPF级别hACE2小鼠由中国医学科学院医学实验动物科学研究所提供,小鼠随机分为两组(n=6),分别为空白溶剂组(空白溶剂灌胃组设为模型组),组合物组(剂量为37.4mg/kg)(即本申请实施例1制备得到的口服液),连续灌胃5天;组合物组灌胃给相应药物,空白溶剂组给予溶剂,连续灌胃给药5天。小鼠经麻醉后经鼻滴入SARS-CoV-2病毒1×105TCID50/ml,每天观察感染小鼠,记录体重、临床症状和对外部刺激的反应。感染后5天处死小鼠,取肺进行病毒载量分析、细胞因子和趋化因子检测、病理检查检测。
2.3检测
实时荧光定量PCR进行病毒载量分析
组织应用试剂盒RNeasy kit(Qiagen)提取总RNA并进行逆转录。qRT-PCR采用以下循环方案和引物进行:50℃2min,95℃2min,95℃15s,60℃30s,循环40次,此后运行溶解曲线程序95℃15s,60℃1min,95℃45s。用于检测SARS-CoV-2的引物如下:正向引物,5′-TCGTTTCGGAAGAGACAGGT-3′;反向引物,5′-GCGCAGTAAGGATGGCTAGT-3′。
细胞因子和趋化因子检测
使用LEGEND plexTM小鼠炎性因子试剂盒(13-plex)分析细胞因子和趋化因子。取25μL肺组织匀浆,与捕获微球共孵育,洗掉未结合的抗体和样本后,加入生物素标记的检测抗体,最后加入SA-PE与生物素结合发出荧光,通过流式仪分析每一种微球上PE的荧光强度来定量分析样本中可溶蛋白含量,采用LEGENDplexTM数据分析软件进行数据采集和分析。
2.4统计分析
所有数据均使用GraphPad Prism 8.0软件(GraphPad software,Inc)进行分析。组间比较采用双尾非配对t检验。以*p<0.05,**p<0.01确定差异有统计学意义。
2.5结果:
模型对照组和治疗组在感染5天后(days post infection,dpi)的平均体重减轻率分别为:模型对照组感染后体重下降,5dpi体重平均下降率为4.86%;组合物组5dpi体重平均下降率为2.69%。(见附图1)。
模型对照组肺组织平均病毒载量为106.84copies/ml。组合物组肺组织平均病毒载量为106.35copies/ml,与模对照组比较,下降0.491g值。(见附图2)。
小鼠感染后5天,组合物组与模型组比较,肺组织中趋化因子MCP-1、MIP-1α、IP-10以及炎症因子TNF-α、IL-6、IFN-γ、IL-12、IL-17、IL-10、IL-1α均下降。(见附图3-12)。
在肺部病理改变方面,模型对照组表现为中度间质性肺炎,而组合物给药后显著改善肺部炎症(见附图14)。模型对照组6例(6/6)肺组织呈中度间质性肺炎改变(见附图13);组合物组4例(4/6)肺组织呈轻度间质性肺炎改变,2例(2/6)肺组织呈中度间质性肺炎改变。
药效学实验2:组合物对人冠状病毒肺炎的效果
试验场所:中国中医科学院中药研究所生物安全实验室(ABSL-2实验室)
1.试验材料
1.1受试药物
本申请实施例1制备得到的组合物口服溶液。
1.2实验动物
SPF级ICR小鼠,雌雄各半,体质量13~15g,由北京维通利华实验动物技术有限公司提供,合格证号:110011211113827874/110011211113827747,许可证号:SCXK(京)2021-0006。饲养条件:ABSL-2实验室,-20Pa,温度22±1℃,湿度40~50%。
1.3病毒毒株及细胞
1.3.1病毒毒株:人类冠状病毒(HCoV-229E),购于美国ATCC,本实验室传代,-80℃冰箱保存。
1.3.2细胞株:人胚肺上皮细胞(MRC-5)购自北京北纳创联生物技术研究院,本室传代,液氮保存。
1.4实验试剂
1.5试验仪器
仪器名称 | 型号 | 生产厂家 | 仪器用途 |
A2型生物安全柜 | Thermo MSC1.8 | 美国Thermo公司 | 动物感染、解剖 |
电子天平 | YP1002 MAX100g | 上海越平科学仪器有限公司 | 称量小鼠体重 |
智能人工气候箱 | 宁波江南仪器厂 | RXZ-380B型 | 动物造模 |
电子分析天平 | AR1140 MAX110g | 美国Ohaus公司 | 称量药物、试剂 |
电子天平 | AL204 MAX210g | 梅特勒-托利多仪器公司 | 称量组织重量 |
IVC小鼠饲养笼 | ZJ-4 | 苏州冯氏股份有限公司 | 饲养小鼠 |
Real-Time PCR仪 | Applied biosystems | QuantStudio 5 | 核酸检测 |
八连排管迷你离心机 | Kylin-Bell Lab | LX-300 | 核酸检测 |
迷你涡旋振荡器 | 海门市其林贝尔仪器公司 | OL-901 | 核酸检测 |
多功能酶标仪 | 德国PerkinElmer公司 | Enspire型 | 炎性因子检测 |
流式细胞仪 | 美国BD公司 | FACSAriaTMllu型 | T、B淋巴细胞检测 |
离心机 | 德国eppendorf公司 | Centrifuge 5430 | 离心细胞 |
低温高速离心机 | 德国eppendorf公司 | Eppendorf-5810R | 离心血清及肺组织 |
2.试验方法
2.1剂量设计及药物配制
2.1.1受试药物:根据推荐剂量方案,将剂量换算为小鼠用量后,采用74.8mg/kg、37.4mg/kg、18.7mg/kg和9.35mg/kg。按0.2ml/10g体重/次灌胃给药,1次/日,连续3天。
2.2病毒传代
取已长成单层MRC-5细胞的25cm2培养瓶,倒掉培养液,用细胞维持液冲洗细胞面3遍后,加入HCoV-229E的病毒液200μl,置37℃5%CO2培养箱中培养,每日倒置显微镜下观察细胞病变情况,共72-96h,直至80%细胞出现明显病变(CPE)后,将细胞培养瓶置于-80℃低温冰箱冻存,病毒液反复冻融3次后,用于检测病毒毒力。
2.3病毒滴度测定
取已长成单层MRC-5细胞的培养板,倒掉培养液,用细胞维持液冲洗细胞面3遍后,按10倍稀释接种不同滴度的HCoV-229E病毒液,10-1~10-8共8个稀释度,100μl/孔,每个浓度4个复孔,同时设正常细胞对照。置37℃5%CO2培养箱中培养,每日倒置显微镜下观察细胞病变情况,共72~96h,记录各孔的细胞病变情况。按Reed-Muench法计算50%细胞病变浓度(TCID50)。
2.4分组及检测
取ICR小鼠80只,按体重等级随机分为正常对照组、单纯229E感染对照组、单纯寒湿刺激对照组(以下简称寒湿证模型组)、寒湿疫毒袭肺病证结合模型组(以下简称疫毒袭肺模型组)、组合物74.8mg/kg组、组合物37.4mg/kg组、组合物18.7mg/kg组、组合物9.35mg/kg组,每组10只,雌雄各半。除正常对照组和229E感染组外,其余小鼠每天置于90±3%相对湿度,无风,温度4±2℃的人工气候箱中,每次4小时刺激后取出,连续7天。
除正常对照组和寒湿证模型组外,其余小鼠于寒湿刺激第5天,用异氟烷轻度麻醉后,以100TCID50HCOV-229E病毒液滴鼻感染,50μl/只;正常对照组及寒湿证模型组用无病毒培养液滴鼻。感染当天各给药组开始给药,给药容积0.2ml/10g体重,每日1次,连续3天;正常对照组、寒湿证模型组、229E感染组、疫毒袭肺模型组在同等情况下给予蒸馏水灌胃。感染第4天称重后处死取肺称重观察并检测下列指标:
2.4.1肺指数及抑制率:小鼠处死取肺称重,按下述公式计算肺指数及肺指数抑制率
肺指数=[肺湿重(g)/体重(g)]×100
2.4.2肺组织中核酸检测(RT-PCR法):小鼠解剖后将肺组织分装在裂解介质中,置于-80℃低温冰箱中保存,检测时从-80℃低温冰箱中取出,每管加入1ml TRIzol Reagent,置于震荡裂解仪上裂解20-25s,取下后室温孵育10min,4℃,12000rpm,离心10min;将澄清上清液移入新的1.5ml离心管中;加入0.2ml氯仿,盖紧管盖,用力摇动离心管15s,室温孵育2-3min至液体分层;4℃,12000rpm,离心15min;将透明上清液小心移入新的1.5ml离心管中,加入0.5ml异丙醇,混匀,室温孵育30min;4℃,12000rpm,离心10min;弃去上清,用1ml75%乙醇轻洗沉淀(使白色沉淀轻轻飘起);4℃,7500rpm,离心5min;吸尽上清液,短暂干燥RNA沉淀5-10min;用30μl DEPC水溶解沉淀,-80℃低温冰箱保存。
对照品核酸处理:DEPC-H2O作为阴性对照。阳性对照品进行10、100、1000倍梯度稀释。
试剂配制:取n×18μl HCoV-229E核酸荧光PCR检测混合液,n×1μl内部对照品,与n×1μl RT-PCR酶(n为反应管数),振荡混匀数秒,3000rpm离心数秒。
加样:取上述混合液20μl置于PCR管中,然后将样品核酸提取液、DEPC-H2O、阳性对照品各5μl分别加入PCR管中,盖紧管盖,离心数秒使所有液体置于底部,立即进行PCR扩增反应。
循环参数设置为:45℃×10min;95℃×15min;再按95℃×15sec→60℃×60sec,循环40次;单点荧光检测在60℃,反应体系为25μl。
2.4.3小鼠血清胃泌素(GAS)、胃动素(MTL)及肺组织中炎性因子检测(Elisa法):血清样本:小鼠摘眼球取血,放置在室温静置30min,3000rpm离心10min,吸取上清至新的EP管内-20℃保存。检测时按照试剂盒说明书操作,酶标仪450nm吸光度检测各指标。
肺组织匀浆液样本:小鼠取肺组织称重后,分装收集小鼠肺组织,-4℃保存。称量50mg肺组织加入500μL生理盐水后,使用超声细胞破碎仪匀浆组织,使用低温高速离心机4℃1000rpm离心10分钟。吸取上清液后分装,保存于-80℃冰箱贮存备用。检测时按照试剂盒说明书操作,酶标仪450nm吸光度检测各指标。
2.4.4小鼠外周血T淋巴细胞亚群及B淋巴细胞比例流式检测:小鼠摘眼球取血,向装有10ml 1×PBS的15ml离心管中加入3滴血(约150μl),1600rpm,5min,室温离心;用移液管小心弃去上清,每管加入1ml红细胞裂解液重悬细胞沉淀,室温裂解约5-10min至液体从浑浊变澄清,加入10ml PBS终止裂解,2000rpm,5min,4℃离心,弃上清。细胞沉淀用10mlPBS重悬,2000rpm,5min,4℃离心,弃上清,用200μl封闭液(含5%FBS的PBS)重悬,并将细胞悬液转移至1.5ml ep管中,4℃封闭30min。避光于封闭液中配制流式抗体如下:FITC标记抗小鼠CD3e、PE标记抗小鼠CD19,PerCP-Cy5.5标记抗小鼠CD4、APC标记抗小鼠CD8a,每一管细胞的配制体积为:抗体各0.3μl,封闭液50μl。
细胞悬液4℃,2000rpm,离心5min,弃上清。加入流式抗体,每管50μl,4℃避光孵育30min,加入1ml PBS,4℃,2000rpm,离心5min,弃上清。用200μl含2%FBS的PBS重悬细胞,转移至流式管中,上机检测。
2.4.5小鼠肺组织病理检测
小鼠取肺后,将肺组织固定于10%福尔马林溶液中,48小时后取出流水冲洗,梯度乙醇脱水,二甲苯透明,浸蜡包埋,切片,HE染色,中性树胶封片,显微镜下观察、照相。光学显微镜下观察小鼠肺部有无病理形态学改变,进行组间比较。
镜下观察标准:
“-”:小鼠肺间质未见有瘀血、水肿,肺内细支气管周围未见有炎症渗出,组织结构正常。
“+”:小鼠肺间质未见有渗出,肺泡未见有增大,肺间质有散在瘀血,有少量渗出,细胞未见有增生;肺内细支气管未见有明显炎症渗出。结构正常。
“++”:小鼠肺组织肺泡未见有明显增大,肺间质有散在的红血球渗出,间质有小片状炎性渗出;细支气管周围有小片状炎性渗出,以淋巴细胞为主,少量嗜酸细胞。
“+++”:小鼠肺间质内有大片状炎症渗出,以组织细胞、淋巴细胞、嗜酸细胞为主,小血管内瘀血,血管膜变性,内膜细胞移位,排列紊乱。肺内细支气管周围炎症渗出。
“++++”:小鼠肺间质大面积出血、炎症渗出,细胞增生、肥大,淋巴细胞、嗜酸性细胞明显增多。小血管嗜酸性变,内膜细胞移位,排列紊乱,细胞大小不均匀,病变较重、较弥漫。肺内细支气管周围明显炎症渗出,以淋巴细胞为主。
2.5统计学方法:单因素方差分析组间比较。
3.结果
3.1组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺指数的影响
表1结果所示:小鼠在寒湿环境和人冠状病毒229E感染双重刺激后,肺指数明显升高,与正常组比较有显著性差异(p<0.01),小鼠给药后,组合物各剂量组均能显著将降低小鼠肺指数,与模型组比较有显著性差异(p<0.01),表明组合物对人冠状病毒肺炎寒湿疫毒袭肺证小鼠病证结合模型具有明显的治疗作用。
表1组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺指数的影响
注:与正常对照组比较##p<0.01;与疫毒袭肺模型组比较**p<0.01。
3.2组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺部病毒载量的影响
表2结果显示:正常组和单纯寒湿刺激组的小鼠肺部几乎没有病毒核酸的表达,而229E感染组和寒湿疫毒袭肺组小鼠肺组织中病毒核酸高表达。给药后,组合物各剂量组均能不同程度降低小鼠肺组织中病毒载量,与模型组比较有显著性差异(p<0.01)。
表2组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺组织病毒载量的影响
注:与正常对照组比较##p<0.01;与疫毒袭肺模型组比较**p<0.01。
3.3组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺组织中炎症因子的影响
表3结果显示:小鼠经过寒湿+人冠状病毒229E双重刺激后,体内IL-6、IL-10、TNF-α、IFN-γ均显著升高,与正常组比较有显著性差异(p<0.01),组合物各剂量组的各项炎症因子显著降低,与模型组比较有显著性差异(p<0.01)。
表3组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺部炎症因子的影响
注:与正常对照组比较##p<0.01;与疫毒袭肺模型组比较**p<0.01,*p<0.05。
3.4组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠血清中证型因子的影响
表4结果显示:寒湿和人冠状病毒229E双重刺激会使小鼠胃动素含量明显升高、胃泌素含量明显降低。与正常组比较有显著性差异(p<0.01),小鼠给药后,组合物各剂量组均能够有效改善寒湿疫毒侵袭导致的胃肠道反应,有效改善胃动素、胃泌素紊乱的情况,与模型组比较有显著性差异(p<0.01)。
表4组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠血清中证型因子的影响
注:与正常对照组比较##p<0.01;与疫毒袭肺模型组比较**p<0.01。
3.5组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠外周血淋巴细胞的影响
表5结果显示:人冠状病毒寒湿疫毒袭肺证病证结合小鼠外周血CD8+T细胞比例显著降低,与正常组比较有显著性差异(p<0.01)。给药干预后,组合物74.8mg/kg组能够显著缓解其降低,与模型组比较有显著性差异(p<0.05,p<0.01)。
表5组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠外周血淋巴细胞的影响
注:与正常对照组比较##p<0.01;与疫毒袭肺模型组比较*p<0.05。
3.6组合物对人冠状病毒炎寒湿疫毒袭肺小鼠肺组织及支气管病变的影响
表6结果显示:病理学镜下观察,人冠状病毒寒湿疫毒袭肺证病证结合小鼠肺间质内有大片状炎症渗出,小血管内瘀血,血管膜变性,内膜细胞移位,排列紊乱,肺内细支气管周围炎症渗出明显,病变等级与正常对照组比较有显著性差异(p<0.01)。小鼠给药后,组合物各剂量组能够减轻支气管炎症渗出状况,红肿相对消退,并且缓解病毒感染所致肺泡、肺间质渗出炎症及红血球渗出情况,使淤血病变相对减轻,病变等级与模型组比较有显著性差异(p<0.05,p<0.01)。
表6-1组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠支气管的影响
表6-2组合物对人冠状病毒肺炎寒湿疫毒袭肺小鼠肺组织的影响
Claims (8)
1.一种治疗和预防新型冠状病毒的组合物,其活性成分及其重量份为:厚朴酚55.7-223份,伪麻黄碱10.7-43份,番泻苷A 5.2-20.6份,槲皮素4.3-17.2份,苯甲酰芍药苷2.5-10.3份,异甘草素0.43-1.72份,黄芪甲苷1.3-5.2份。
2.如权利要求1所述的治疗和预防新型冠状病毒的组合物,其活性成分及其重量份为:厚朴酚100-180份,伪麻黄碱20-35份,番泻苷A 8.4-15.8份,槲皮素7.5-15.2份,苯甲酰芍药苷4.5-9.6份,异甘草素0.56-1.35份,黄芪甲苷2.1-4.5份。
3.如权利要求2所述的治疗和预防新型冠状病毒的组合物,其活性成分及其重量份为:厚朴酚100份,伪麻黄碱20份,番泻苷A 8.4份,槲皮素7.5份,苯甲酰芍药苷4.5份,异甘草素0.56份,黄芪甲苷2.1份。
4.如权利要求2所述的治疗和预防新型冠状病毒的组合物,其活性成分及其重量份为:厚朴酚180份,伪麻黄碱35份,番泻苷A 15.8份,槲皮素15.2份,苯甲酰芍药苷9.6份,异甘草素1.35份,黄芪甲苷4.5份。
5.如权利要求2所述的治疗和预防新型冠状病毒的组合物,其活性成分及其重量份为:厚朴酚111.5份,伪麻黄碱21.5份,番泻苷A 10.3份,槲皮素8.6份,苯甲酰芍药苷5.15份,异甘草素0.86份,黄芪甲苷2.6份。
6.如权利要求1-5任一项所述的治疗和预防新型冠状病毒的组合物,该组合物制成药物的剂型为颗粒剂、片剂、胶囊、口服液或注射剂。
7.一种治疗和预防新型冠状病毒的药物,其特征为,将权利要求1-5任一项所述的治疗和预防新型冠状病毒的组合物与药学上可接受的载体或赋形剂制成药物制剂。
8.权利要求1-6中任意一项所述的组合物或权利要求7所述的药物在制备治疗或预防新型冠状病毒的药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310241187.3A CN116327791A (zh) | 2023-03-14 | 2023-03-14 | 一种治疗和预防新型冠状病毒的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310241187.3A CN116327791A (zh) | 2023-03-14 | 2023-03-14 | 一种治疗和预防新型冠状病毒的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116327791A true CN116327791A (zh) | 2023-06-27 |
Family
ID=86875664
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310241187.3A Pending CN116327791A (zh) | 2023-03-14 | 2023-03-14 | 一种治疗和预防新型冠状病毒的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116327791A (zh) |
-
2023
- 2023-03-14 CN CN202310241187.3A patent/CN116327791A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11986553B2 (en) | Multi-component injection | |
CN111888435B (zh) | 一种抗冠状病毒的中药组合物及其在治疗炎症中的用途 | |
Fan et al. | Effects of Astragalus polysaccharide liposome on lymphocyte proliferation in vitro and adjuvanticity in vivo | |
CN111297969A (zh) | 柴银制剂在制备抗冠状病毒药物中的应用及其制备方法 | |
CN111588721B (zh) | 化合物zl0580用于制备预防或治疗非洲猪瘟药物的新用途 | |
CN113713059B (zh) | 宣肺败毒方用于制备预防和/或治疗甲型h1n1流感病毒引起的肺炎的药物中的用途 | |
CN112791084B (zh) | Ml-60218在制备用于治疗非洲猪瘟的药物中的新用途 | |
US10675317B2 (en) | Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders | |
US9303006B2 (en) | Line leaf inula flower lactone A and methods for preparing and using the same for treating myocarditis | |
CN112750496A (zh) | 一种covid-19棘突状蛋白的小分子抑制剂的筛选方法、其筛选的活性分子及用途 | |
CN114053343A (zh) | 一种中药组合物、制备方法及应用 | |
CN107737201B (zh) | 三叶青提取物抗病毒作用应用 | |
CN101869595A (zh) | 甘胆口服液的制备和质量检测方法 | |
CN116327791A (zh) | 一种治疗和预防新型冠状病毒的组合物及其制备方法 | |
EP4279088A1 (en) | Exosomes comprising coronavirus-derived antigen protein or gene encoding same protein, and use of same | |
CN103356812B (zh) | 一种了哥王颗粒 | |
CN105853406B (zh) | 原花青素在制备防治猪繁殖与呼吸综合征药物中的用途 | |
CN111588725B (zh) | 化合物arv-825用于制备预防或治疗非洲猪瘟药物的新用途 | |
CN114767706A (zh) | 玉竹多糖在制备治疗哮喘的药物中的应用 | |
RU2366697C2 (ru) | Средство, обладающее системным действием, его применение, фармкомпозиции, способы лечения и профилактики | |
CN114668805A (zh) | 组合物在制备药物中的用途 | |
CN111265610A (zh) | 咳清胶囊在治疗冠状病毒感染引发的疾病中的应用 | |
CN111150798A (zh) | 咳速停糖浆在治疗冠状病毒感染引发的疾病中的应用 | |
CN116059276A (zh) | 抗猪流行性腹泻病毒的药物组合物及其制备方法和应用 | |
CN115040547A (zh) | 一种提高外周血单个核细胞线粒体功能的药物及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |